Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma

Host: Ryan Quigley <br> <p>In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this <i>AudioAbstract,</i> ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life. </p>